PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30093840-7	2018	Concurrent expression of miR-125a and miR-205 via the miRNA cluster transfection significantly enhanced trastuzumab-mediated growth inhibition and cell cycle G1 arrest in BT474 cells and markedly increased paclitaxel-induced apoptosis in another HER2-overexpressing breast cancer cell line HCC1954.	Paclitaxel	206-216	microRNA 205	Homo sapiens	38-45	
30982496-0	2019	miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1.	Paclitaxel	26-36	microRNA 205	Homo sapiens	0-7	
30019863-0	2018	Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.	Paclitaxel	138-143	microRNA 205	Homo sapiens	46-53	
30019863-2	2018	OBJECTIVES: In this study, we aimed to investigate the expression pattern of let-7a and miR-205 tumorsuppressor miRNAs in breast cancer cell lines under treatment with paclitaxel.	Paclitaxel	168-178	microRNA 205	Homo sapiens	88-95	
27362808-6	2016	We found miR-205 downregulated in both MCF-7/A02 and CALDOX cells, two drug-resistant derivatives of MCF-7 and Cal51 cells, and its ectopic expression led to an increase in apoptosis resensitization of both drug-resistant cell lines to doxorubicin and taxol.	Paclitaxel	252-257	microRNA 205	Homo sapiens	9-16	
26305791-0	2015	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.	Paclitaxel	177-187	microRNA 205	Homo sapiens	36-43	
25137071-0	2014	Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.	Paclitaxel	165-175	microRNA 205	Homo sapiens	24-31	
25137071-14	2014	CONCLUSIONS: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.	Paclitaxel	155-165	microRNA 205	Homo sapiens	44-51